Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 8Lymphoma, T-Cell, Cutaneous 6Lymphoma, Large-Cell, Anaplastic 5Lymphoma, T-Cell, Peripheral 4Mycosis Fungoides 3Lymphoma 3Immunoblastic Lymphadenopathy 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mesothelioma, Malignant 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Urethral Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma 1

Interventions

Rituximab 226Cyclophosphamide 202fludarabine phosphate 108Peripheral Blood Stem Cell Transplantation 103Filgrastim 87Etoposide 76Cytarabine 70ibrutinib 68Mycophenolic Acid 67Bortezomib 66Whole-Body Irradiation 63Cyclosporine 63Melphalan 59Lenalidomide 59Bendamustine Hydrochloride 58Vincristine 53Radiotherapy 53fludarabine 52Tacrolimus 50Doxorubicin 48Busulfan 48Methotrexate 47Antilymphocyte Serum 42Prednisone 41Carmustine 40Dexamethasone 38Granulocyte Colony-Stimulating Factor 33venetoclax 32acalabrutinib 31zanubrutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Depsipeptides × Clear all
NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡